Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$58.93 - $96.12
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.61M
Market Cap
$41.42B
Enterprise Value$35.79B
Total Cash (Recent Filing)$3.05B
Total Debt (Recent Filing)$700.00M
Price to Earnings (P/E)29.6
Beta1.19
Next Earnings
Apr 24, 2025EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.38
Shares Outstanding587,900,000
10 Day Avg. Volume4,928,882
30 Day Avg. Volume4,614,964
Financial Highlights & Ratios
PEG Ratio8.84
Price to Book (P/B)N/A
Price to Sales (P/S)7.62
Price to Cash Flow (P/CF)-81.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.28
Enterprise Value/Ebitda19.73
Forecast
1Y Price Target
$77.50Price Target Upside9.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
---
Edwards Lifesciences News
See All EW News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEW delivered 4Q results that outpaced Street expectations.
Guidelines And CoverageThe final National Coverage Decision (NCD) will cover Evoque for the Medicare population and is more favorable than the proposed NCD.
Product PerformanceEW is pleased with S3 Ultra Resilia's commercial performance in both the US and Europe.
Bears Say
Growth ProjectionsUltimately, if TAVR continues to be a mid-single-digits growth business, analysts will continue to wait on the sidelines for the stock.
Guidance And Growth ExpectationsManagement reiterated guidance for FY25, but the Q1 TAVR guidance raised questions due to expected growth rates being below the low end of FY25 expectations.
Market CompetitionEdwards Lifesciences acknowledged a loss of TAVR share in Japan due to more aggressive pricing from competitors.
---
Ownership Overview
0.93% Insiders
22.39% Mutual Funds
19.18% Other Institutional Investors
32.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $58.93 and its highest was $96.12 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $41.42B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Apr 24, 2025 which is in 30 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Feb 11, 2025. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.551 by $0.039.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.6.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 587,900,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.59 in its last earnings report, beating expectations of $0.551. Following the earnings report the stock price went up 6.924%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
---
Edwards Lifesciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$77.50 (9.99% Upside)
$77.50 (9.99% Upside)
Blogger Sentiment
Bullish
EW Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $873.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.58%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
39.43%
Trailing 12-Months
Company Description
Edwards Lifesciences
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
EW Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive sentiment with strong sales growth, especially in TMTT, strategic acquisitions, and a positive outlook for future growth. Despite some challenges in TAVR growth and regional pressures, the company maintained a strong balance sheet and is optimistic about 2025.Read More>---
EW Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
18.04% Surgical Structural Heart
6.47% Transcatheter Mitral and Tricuspid Therapies
---
EW Stock 12 Month Forecast
Average Price Target
$77.50
▲(9.99% Upside)
Technical Analysis
Best Analysts Covering EW
1 Year
1 Year Success Rate
22/32 ratings generated profit
1 Year Average Return
+11.26%
reiterated a buy rating 4 months ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +11.26% per trade.
---